Indications |
Oral Hypertension Adult: Initially, 40 mg once daily. Max: 80 mg/day. Renal impairment: Severe impairment/ Haemodialysis: Initial dose 20 mg/day. Hepatic impairment: Mild to moderate: Max 40 mg/day. Severe: Contra-indicated Special Populations: Renal impairment: Lower doses should be considered. |
Contraindications |
Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation. |
Warnings / Precautions |
Hepatic insufficiency, biliary obstruction, renal impairment, renaly artery stenosis. Correct volume depletion before initiating treatment. Monitor serum potassium levels regularly, especially in elderly and renally-impaired patients. |
Adverse Reactions |
URTI, dizziness, back pain, sinusitis, pharyngitis and diarrhoea. Slight elevations in liver enzymes. Potentially Fatal: Rarely angioedema, rash, pruritus and urticaria. |
Overdose Reactions |
Hypotension, dizziness, tachycardia or bradycardia. Supportive treatment to be instituted. Not removed by haemodialysis. |
Drug Interactions |
Concurrent use increases digoxin concentration; increases risk of lithium toxicity; increases risk of hyperkalaemia with potassium sparing diuretics, heparin. See Below for More telmisartan Drug Interactions |
Food Interactions |
Food slightly reduces the bioavailability. |
Mechanism of Actions |
Telmisartan is a nonpeptide AT1 angiotensin II receptor antagonist. Exerts antihypertensive activity by preventing angiotensin II from binding to AT1 receptors thus inhibiting the vasoconstriction and aldosterone-secreting effects of angiotensin II. Absorption: Rapidly absorbed. Dose dependent bioavailability 42% (after 40 mg dose); 58% (after 160-mg dose). Peak plasma concentrations: 0.5-1hr. Distribution: Protien binding: 99%. Metabolism: Undergoes conjugation with glucuronic acid to form inactive metabolites. Excretion: Excreted almost entirely as unchanged drug in faeces via bile. <1% excreted via urine. Terminal elimination half-life: 24 hr. |
Administration |
May be taken with or without food. |
Storage Conditions |
Oral: Store at 15-30°C. |
ATC Classification |
C09CA07 - telmisartan ; Belongs to the class of angiotensin II antagonists. Used in the treatment of cardiovascular disease. |
Storage |
Oral: Store at 15-30°C. |
Available As |
|
Telmisartan
One Response to Telmisartan
Post Review about Telmisartan Click here to cancel reply.
Telmisartan Containing Brands
Telmisartan is used in following diseases
Drug - Drug Interactions of Telmisartan
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
Price TELMISARTAN 80 MG